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Abstract
Introduction Breast cancer is the most commonly diagnosed
cancer in women worldwide and consequently has been
extensively investigated in terms of histopathology,
immunochemistry and familial history. Advances in genome-
wide approaches have contributed to molecular classification
with respect to genomic changes and their subsequent effects
on gene expression. Cell lines have provided a renewable
resource that is readily used as model systems for breast cancer
cell biology. A thorough characterization of their genomes to
identify regions of segmental DNA loss (potential tumor-
suppressor-containing loci) and gain (potential oncogenic loci)
would greatly facilitate the interpretation of biological data
derived from such cells. In this study we characterized the
genomes of seven of the most commonly used breast cancer
model cell lines at unprecedented resolution using a newly
developed whole-genome tiling path genomic DNA array.
Methods Breast cancer model cell lines MCF-7, BT-474, MDA-
MB-231, T47D, SK-BR-3, UACC-893 and ZR-75-30 were
investigated for genomic alterations with the submegabase-
resolution tiling array (SMRT) array comparative genomic
hybridization (CGH) platform. SMRT array CGH provides tiling
coverage of the human genome permitting break-point
detection at about 80 kilobases resolution. Two novel discrete
alterations identified by array CGH were verified by
fluorescence in situ hybridization.
Results Whole-genome tiling path array CGH analysis
identified novel high-level alterations and fine-mapped
previously reported regions yielding candidate genes. In brief,
75 high-level gains and 48 losses were observed and their
respective boundaries were documented. Complex alterations
involving multiple levels of change were observed on
chromosome arms 1p, 8q, 9p, 11q, 15q, 17q and 20q.
Furthermore, alignment of whole-genome profiles enabled
simultaneous assessment of copy number status of multiple
components of the same biological pathway. Investigation of
about 60 loci containing genes associated with the epidermal
growth factor family (epidermal growth factor receptor, HER2,
HER3 and HER4) revealed that all seven cell lines harbor copy
number changes to multiple genes in these pathways.
Conclusion The intrinsic genetic differences between these cell
lines will influence their biologic and pharmacologic response as
an experimental model. Knowledge of segmental changes in
these genomes deduced from our study will facilitate the
interpretation of biological data derived from such cells.
Introduction
Breast cancer is the most prevalent cancer worldwide and is
the second leading cause of cancer-related deaths in women
in North America [1,2]. It is a complex disease in which multi-
ple genetic factors can combine to drive pathogenesis [3-5].
Changes in copy numbers of genes such as ERBB2 and c-
MYC have been extensively documented in breast cancer and
are present in model cell lines [6-9]. Amplified (and overex-
pressed) genes are prime therapeutic targets as for example,
the use of the drug trastuzumab against ERBB2 has been
shown to improve breast cancer survival rates alone or in com-
bination with other treatments [10-12].
Strategies to detect gene copy number alterations will facili-
tate the identification of novel molecular targets. Previous
studies with 10-megabase (Mb) resolution conventional
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metaphase comparative genomic hybridization (CGH) have
identified gross regions of recurrent chromosomal aberrations
in multiple breast cancer cell lines including loci within chro-
mosomes 1q, 8q, 11q13, 17q and 20q13. Many of these alter-
ations proved to be relevant because they were also present
in primary tumors investigated [13-15]. Recent advances in
array CGH have greatly improved the resolution of this tech-
nology, enabling the detection of segmental copy losses and
gains [16,17]. Regional genomic arrays, providing contiguous
or tiling coverage of a locus of interest, have been constructed
for the fine mapping of commonly altered regions in breast
cancer (such as 20q13) [18-20]. Whole chromosome arrays
have been used to provide information at 500 kb intervals. For
example, a chromosome 17 array was used to identify 13
regions of change present in breast cancer cell line models
and primary breast cancers [21]. Similarly, a genome-wide
array containing nearly 2,500 bacterial artificial chromosome
(BAC) clones with a resolution at about 1.4 Mb was used to
illustrate the detection of copy number alterations (CNAs) in
various breast cancer cell lines [22]. Recently, a separate
study using an array of 422 genomic loci detected frequent
alterations at 1, 6, 7p, 9, 11q, 12q, 17, 20q and 22q in archival
breast cancer specimens [23]. cDNA arrays have also
detected DNA copy changes of amplicons containing ERRB2
on 17q [24-27]. More recently, a cDNA array containing 6,691
mapped human genes was used to explore the relationship
between copy number alteration and gene expression
changes in breast tumors and cell lines [28]. While large-insert
clone megabase-interval CGH arrays and cDNA arrays pro-
vide a robust platform for the rapid survey of tumor genomes,
valuable information could be overlooked as a result of their
limited resolution. It is clear that a more detailed description of
breast tumor genomes would require re-examination with a
higher-resolution array platform.
Genetic, biochemical and pharmacologic studies of breast
cancer have been greatly dependent on several commonly
used model breast cancer cell lines: MCF-7, BT-474, SK-BR-
3, T-47D, UACC-893, MDA-MB-231 and ZR-75-30. That is, a
summation of studies involving at least one of these seven cell
lines produces over 13,500 hits on Medline. These cells are
known to harbor gross chromosomal aberrations; measuring
the precise segmental copy number status across their entire
genome may uncover novel discrete changes. In the current
study we expanded the use of array CGH to survey the
genomes of these breast cancer cells at unprecedented detail
with a recently developed whole-genome tiling path array that
covered the genome with 32,433 overlapping BAC clones
[29]. Analysis at this resolution has led to the identification of
novel features in these genomes and to the delineation of seg-
mental genetic alterations that have escaped detection by
conventional molecular cytogenetic techniques and previous
marker-based or interval array CGH analysis.
Materials and methods
Cell line DNA
A panel of seven breast cancer-derived cell line DNA was
obtained from the American Type Culture Collection: MCF-7,
T-47D, Sk-Br-3, MDA-MB-231, BT-474, UACC-893 and ZR-
75-30. Pooled normal female DNA was used as reference for
all array CGH experiments (Novagen, Mississauga, ON, Can-
ada). DNA was quantified with a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE, USA).
Array CGH
The seven cell lines were assayed for genetic alterations with
a whole-genome tiling path BAC array in comparative genomic
hybridization experiments. The submegabase-resolution tiling
set (SMRT) array contains 32,433 overlapping BAC-derived
DNA segments that provide tiling coverage over the human
physical genome map. All clones were spotted in triplicate,
resulting in 97,299 elements over two sides [29-31]. A
detailed protocol is provided in Additional file 1.
Imaging and analysis
Hybridizations were scanned with an imaging system based
on a charge-coupled device (Arrayworx eAuto; Applied Preci-
sion, Issaquah, WA, USA) and analyzed with SoftWoRx
Tracker Spot Analysis software. Stringent criteria were applied
to filter spot intensity data. A standard deviation greater than
0.075 between triplicate spots was deemed unreliable and
such spots were therefore excluded from our analysis [29].
Only data points with a ratio of signal intensity to background
intensity noise exceeding 15 were used in the analysis.
Custom software (SeeGH) was used to visualize log2 ratios of
clones with respect to location in the genome [32,33].
Because of the complexity of the genomes of these cell lines
with respect to ploidy, we have set thresholds for high-level
gains and losses to +0.8 and -0.7, respectively, to limit the
number of regions for discussion. This threshold encom-
passes high-level or multi-copy changes previously reported
while excluding the abundant number of low-level or single-
copy changes common to these cell lines. The complete data
set has been made publicly available for further inquiry. In addi-
tion, only those loci containing two or more altered overlapping
clones were included in the analysis to reduce false positives,
and breakpoints were confirmed with the publicly available
aCGH-smooth software [34,35].
Fluorescence in situ hybridization
For fluorescence in situ hybridization (FISH) probe synthesis,
DNA samples from BAC clones RP11-118L18, RP11-
419H8, RP11-813P3 and RP11-790I13 were amplified with
a modified ligation-mediated polymerase chain reaction proto-
col as described previously [31]. Imaging and analysis were
performed as described previously [36].Available online http://breast-cancer-research.com/content/8/1/R9
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Results and discussion
Whole-genome tiling path analysis of segmental 
alterations
SMRT array CGH technology provides a tool for assessing
genomic aberrations comprehensively in great detail. Compre-
hensive genomic profiles of segmental gains and losses for
seven commonly used breast cancer model cell lines were
revealed with this technology. Because of the large amount of
data generated, we present the complete genomic profiles
and frequency analysis in Additional files 2, 3, 4, 5, 67 and 8
(Figure 1). The raw data of the signal intensity ratios of the
97,299 spots for each array CGH experiment have been made
publicly available [33] and also deposited at the gene expres-
sion omnibus (GEO) database at NCBI, series accession
number GSE3106.
Figure 1 demonstrates the details of a tiling path SeeGH kary-
ogram, summarizing SMRT array CGH results for cell line
UACC-893. Whole chromosomal arm gains can be seen at
1q, 5p, 7p, 8q and 10p, whereas arm losses are evident at 3p,
4p, 5q, 8p, 13q, 17p, 19p, 20p and Xp. Smaller segmental
changes such as the telomeric gained region of 6p or loss at
10q are readily detected. Complex alterations indicating multi-
ple levels of change are denoted by higher-level peaks embed-
ded within a region of change, for example the central region
of the 2p arm. The magnified display of 17q demonstrates the
Figure 1
Comprehensive submegabase-resolution tiling set (SMRT) array comparative genomic hybridization profile of cell line UACC-893 Comprehensive submegabase-resolution tiling set (SMRT) array comparative genomic hybridization profile of cell line UACC-893. Whole-genome 
SeeGH karyogram UACC-893. Individual data points denote log2 ratios plotted to corresponding chromosomal location. Log2 ± 0.5 scale bars are 
included for reference. Displacement of data points to the right and left of the centre line represents gain and loss, respectively. The inset shows a 
magnified view of complex alteration on chromosome 17q.Breast Cancer Research    Vol 8 No 1    Shadeo and Lam 
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identification of a discrete CNA. Beginning at the centromere,
we can see two regions of segmental loss separated by a
high-copy-number amplicon containing the ERBB2 gene. The
centromeric breakpoint of this amplicon is located between
the overlapping regions of clones RP11-25P3 and RP11-
592L16, whereas the telomeric breakpoint is located between
clones RP11-686E5 and RP11-259G21. The second region
of segmental loss at 17q21.1-q21.31 is followed by a large
segmental gain and a second discrete multiple copy amplifica-
tion at 17q25.1.
To establish detection sensitivity, we first examined previously
reported regions of CNA. Our data indicated high-level gains
at the c-MYC locus in SK-BR-3 and MCF-7 (+2.84 and +1.19
log2 ratios, respectively) corresponding to previously reported
change in copy number [7,37,38]. Similarly, BT-474, ZR-75-
30, UACC 893 and SK-BR-3 are known to harbor a high-level
amplification of the ERBB2 locus. SMRT array CGH, in addi-
tion to detecting the ERBB2 locus, revealed several additional
discrete changes on the 17q arm in these cell lines. In another
example, a previously reported homozygous deletion at
3q13.31, detected by a 10K single nucleotide polymorphism
(SNP) array in MCF-7, yielded a log2 ratio of -1.2 in our SMRT
array CGH analysis [39]. Further comparison of SNP data and
SMRT array CGH for cell line BT-474 showed that many of the
alterations detected by SMRT array CGH were not clearly
delineated or were not detected by the SNP platform (Addi-
tional file 9). Although SNP arrays offer the advantage of gen-
otype data, they are only suited to the detection of large-scale
changes in copy number. However, the two technologies are
clearly complementary because each is designed to address
a different question.
Six of the seven cell lines (not MDA-MB-231) were previously
profiled for genomic alterations with the use of a 6,691-gene
cDNA microarray [28]. Pollack and colleagues showed numer-
ous genomic alterations, both gains and losses, which were
correlated with expression patterns on the same array plat-
form. All the CNAs reported were detected by SMRT array
CGH, along with the discovery of numerous novel alterations
when re-evaluated at tiling path resolution. Known and novel
CNAs for the seven genomes are summarized in Table 1. Inter-
estingly, not all CNAs contain annotated genes, which is con-
sistent with the fact that the annotation of coding and non-
coding transcripts within the human genome sequence is a
continuing process.
Novel features of the genome of model cell lines
Among the seven cell lines, 75 regions of high-level (multi-
copy) segmental gains and 48 regions of multi-copy loss were
identified. Because these cell lines serve as model systems for
investigating breast cancer biology, a detailed understanding
of their genetic alterations is essential to the interpretation of
studies with these cell lines. We first describe noteworthy fea-
tures of the individual genomes and then compare across mul-
tiple profiles to identify common alterations.
MCF-7 genome
The MCF-7 genome harbors 21 high-level CNAs, summarized
in Table 1. Remarkably, many of the previously reported
regions of genetic alteration split into multiple segments upon
tiling resolution analysis. The 1p13 amplification described
previously [40] in fact divides into three distinct segments of
high-level amplifications: a 1,300 kb segment at 1p13.3, con-
taining only two genes, those encoding arginine N-methyl-
transferase-6 (PMRT6) and netrin G1 (NTNG1); a 300 kb
segment at 1p13.2, encompassing a single gene, that encod-
ing potassium voltage-gated channel subfamily D member
(KCND3); and a 1,300 kb region at the centromeric end of
1p13.2, containing 20 genes including BCAS2, which has
been shown to be amplified and overexpressed in breast can-
cer cell lines and tumors (Figure 2) [40-42]. Although a loss at
4p15-qter has been reported [14], we observed a 7 Mb loss
at 4q34.3-q35.2. The same group also reported an 11p loss;
however, our data show that this alteration represents a large
45 Mb segment at 11p15.5-p11.2 and an adjacent but dis-
tinct 2 Mb loss at 11p11.2. Similarly, amplifications at the
distal end of 15q [13,14] were fine mapped to reveal a 4.9 Mb
high-level gain at 15q21.1-q21.3 encompassed by clones
RP11-416B20 and 664B9 containing FGF7, CYP19A1 and
MAPK6. A lower-level gain was also observed at 15q22.2-
qter.
BT-474 genome
BT-474 possesses the greatest number of high-level gains
and complex alterations and has previously been profiled with
the SMRT array CGH platform [29]. In brief, the 1q arm
showed multiple rearrangements. A complex aberration at
1q21.2-q25.1 is highlighted by three peaks of high-level gain:
1q21.2-q21.3 (350 kb), 1q22-q23.1 (500 kb) and 1q24.2
(550 kb). In addition, two previously undocumented, distinct
regions of gain were identified at 1q31.3 (1,650 kb) and
1q32.1 (950 kb). Figure 3a shows FISH verification of the
1q32.1 amplicon. Although a 1q42-qter gain has been previ-
ously reported for BT-474 [14] we observed four separate
regions of high-level gain: 1q42.12-q42.13 (500 kb), 1q43
(450 kb), 1q44-q43 (850 kb) and 1q44 (1,700 kb). A 11q13-
q14 gain was redefined by SMRT array CGH as a complex
high-level amplification at 11q13.1-13.5 (19.8 Mb) containing
two distinct and localized high-level peaks at 11q13.1 (700
kb) and 11q13.4 (1,050 kb).
In addition to fine mapping of regions previously reported, sev-
eral prominent novel alterations were detected: high-level
gains at 4q21.1 (2,700 kb), 9p13.3 (2,050 kb), 11q22.1-
q22.2 (3,600 kb), 14q11.2-q21.1 (21 Mb) and 14q31.3-
q32.12 (3,100 kb). Gains of 20q have been well documented
in breast cancer [13,20,23,43]. In BT-474 we observed four
distinct segments with increased copy numbers: 20q11.22Available online http://breast-cancer-research.com/content/8/1/R9
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Table 1
High-level alterations detected by array CGH
Cell line Locus Start clone End clone Size (kb) Locus Start clone End clone Size (kb)
MCF7 Amplifications Deletions
1p13.3 N0451I14 N0228E23 1,290 3q13.31 N0747H24 N0362H11 700
1p13.2 N0099M15 N0795O09 288 4q34.3-35.2 N0442N05 N0746B09 7,100
1p13.2 N0626F04 N0517B05 1,330 6q25.2-27 M2007C03 M2258B24 14,400
3p14.2-14.1 N0669F02 N0589G04 3,180 8p arm p p p
8q21.2-q24.21 N0133G02 N0315E09 43,300 11p15.5-11.2 N0412M16 M2326E01 45,300
15q21.1-21.3 N0416B20 N0664B09 4,930 11p11.2 N0070A09 M2326E01 1,940
17q23.2-24.3 N0716B04 N0203A19 113,200 11q11-q12.1 N0010E21 F0627I09 4,300
Peak: 17q23.2 N0760B22 N0433B24 4,900 11q14.2-23.3 N0282G16 N0004N09 30,000
17q25.1 N0076G04 N0552F03 766 11q23.3-25(tel) N0196E01 N0715D10 15,400
20q12 N0385G02 N0476P15 1,790 13q14.2-34(tel) N0155D15 M2323L19 66,900
20q13.12-20q13.33 (tel) N0272C13 N0476I15 17,500
Peaks: 20q13.12-20q13.13 A N0702E03 N0730O20 1,790
20q13.13 B N0711M06 F0592G15 309
20q13.2 C N0020J08 N0346B03 1,450
20q13.31D N0044A06 N0671P16 411
21q22.13-22.3(tel) N0094J12 N0457P07 8,450
BT474 Amplifications Amplifications
1q21.2-q25.1 15q11.2 -q12 N0607H20 N0208F21 5,030
Peaks: 1q21.2-q21.3A N0035F14 N0714N02 366 Peaks: 15q11.2 A N0552D03 M2200G17 949
1q22-q23.1B N0647N20 N0740J19 510 15q11.2 B N0484P15 N0710L06 624
1q24.2C N0137J06 N0616K15 540 17q12-21.2 N0196P12 N0278E15 4,090
1q31.3 N0662E13 N0141E20 1,661 17q21.32-23.2 N0771D19 M2014K24 13,800
1q32.1 N0783D13 N0617D19 936 Peaks: 17q21.32-q21.33A N0071G24 N0607H13 2,500
1q42.12-q42.13 M2185P06 M2016D17 500 17q22-23.2 B N0515J20 N0473G17 2,180
1q43 N0236L13 N0614N14 449 17q23.2 C N0399O18 N0767P09 1,170
1q44-q43 N0440F10 N0794A13 865 17q24.1-24.3 N0583F02 N0693H11 5,300
1q44 N0778E23 N0071K05 1,720 Peak: 17q24.1 N0583F02 N0394K10 482
4p16.1-15.33 N0270I03 N0652B07 1,210 19p13.2-13.12 N0295M02 N0441D06 6,310
4q21.1 N0598G02 N0772N01 2,700 20p12.1 N0134G22 N0022E15 800
9p13.3 N0069E18 N0795P12 2,060 20q11.22 N0601G07 N0552G16 1,300
9q33.1-34.13 M2248M11 N0738I14 12,600 20q13.11-13.32 N0809G24 N0261P09 14,800
11q13.1-13.5 N0813P09 N0360N22 19,800 20q13.33 N0648D07 N0694I10 305
Peaks: 11q13.1 A N0029K11 N0804F01 704 20q13.33-tel N0305P22 N0134L13 1,380
11q13.4 B N0093M11 N0598G03 1,030 Deletions
11q22.1-22.2 N0795D03 N0347H03 3,560 5q14.1-14.3 N0129E04 N0291O24 5,390
14q11.2-q21.1 N0597A11 N0254B15 21,230 6q24.1 N0709J21 M22024J17 3,200
14q31.3-32.12 N0771O08 N0325L17 3,080 20q11.22 N0171G22 N0774C15 670
20p11.23-13.11 N0712N14 N0464F07 7,140
ZR 75 30 Amplifications Amplifications
8q11.21 N0569I08 N0513O13 682 17q22-23.2 N0349F01 N0153J08 5,600Breast Cancer Research    Vol 8 No 1    Shadeo and Lam 
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8q13.3 N0367C12 N0634L17 538 Peaks: 17q23.2 A N0159D12 M2023J07 298
8q21.2 N0319A24 N0317J10 1,350 17q23.2 B N0381A05 N0634F05 3,560
8q21.3 N0565H20 N0102D03 264 17q23.3-24.1 N0614F05 N0712A10 481
8q22.1 N0381I07 N0103P22 729 Deletions
8q22.2-24.3 N0281D17 N0620H01 45,600 1p36.33-35.3 N0206L10 N0758C04 26,700
Peaks: 8q23.1A N0078J05 N0357L07 907 1p35.2-35.1 N0629A12 N0068H10 775
8q24.12 B N0760H22 N0088J18 1,440 1p34.3 N0452M14 N0020P17 1,510
8q24.22 C N0100J23 N0422I20 440 1p21.2-13.3 N0293L15 N0813H10 10,800
8q24.3 D N0662P06 F0530P15 2,740 4q21.1 N0184F15 N0184J11 151
17q11.1-11.2 N0260A09 N0147N18 3,050 11q13.5-25(tel) N0149B15 M2270L17 57,600
17q12 N0600K04 N0560P04 980 17q11.2-12 N0082D14 N0104J23 6,020
17q12 N0722D15 N0062P03 1,360 17q21.1-21.32 N0278E15 N0046I22 7,700
17q12-21.1 N0689B15 N0032H06 490 17q23.33-22 N0368A16 N0379H09 994
17q21.32-21.33 N0771D19 M2190C10 3,910 17q22 N0466D20 N0515J20 881
21q11.2-q22.11 N0615H23 N0694N16 16,300
UACC 893 Amplifications Deletions
7p21.1 N0116D07 N0746H13 733 11p15.1 N0118A14 N0614L12 995
11q13.3-q14.3 M2011L13 N0613M07 24,700 16p12.1 N0104F06 N0674B07 1,380
11q22.1 N0743I15 N0659E10 619 17p arm p p p
17q12-21.2 N0600J16 N0686E05 1,490
17q21.33-24.2 N0095M07 N0068K09 17,700
17q25.1 N0076G04 N0449J21 999
SKBR3 Amplifications Amplifications
3p22.2 N0091E04 N0325M12 432 17q12-21.2 N0062P03 N0606M07 3,390
3q25.1 N0739J07 N0118L18 678 17q25.3 N0305C04 N0781F24 1,550
3q22.3-q23 N0657M13 N0718H02 2,000 20p arm p p p
3q26.2-q26.31 N0190I05 N0590E04 3,300 20q11.22-11.23 N0454F11 N0254N13 4,510
7q31.1-q32.3 M2023N18 N0019B03 17,800 20q12-13.32 N0434N22 N0290D09 16,200
8q13.3-21.13 N0746L20 N0125J17 10,600 Deletions
8q21.2-21.3 N0509F16 N0561A10 5,950 8q21.3-22.1 N0230C03 N0804A07 6,040
Peaks: 8q21.2 A N0694L21 N0606L16 309 8q22.3-23.1 N0739L19 N0025P11 4,920
8q21.3B N0129P07 N0196C06 559 8q24.22 N0015L05 N1147M08 1,570
8q21.3 C N0627A06 N0529J09 499 8q24.23-24.3 N0467B24 N0613F12 3,810
8q23.2-24.21 N0114O08 N0294P07 17,100 10q22.3-25.2 N0635P19 N0257E05 30,900
Peaks: 8q23.3 A N0058O03 N0531C21 746 12q23.3-24.11 N0061L24 M2155D19 1,380
8q23.3 B N0164M09 M2118B16 365 12q24.21-24.31 N0412G23 N0138I16 5,360
8q24.12 C N0389M07 N0047A23 821 17q11.2-12 N0634A23 N0607B02 6,460
8q24.21 D N0288B17 N0294P07 716 17q21.2-23.2 N0400F19 N0767P09 18,100
10q21.1-22.3 N0195P24 N0506E07 25,500 18q12.2-21.2 N0645I23 N0664P08 20,400
14q31.3-32.12 N0046B20 N0386D20 7,020 19p13.11 N0715L15 N0723M22 4,710
17q11.1-11.2 N0458L21 N0193M11 3,170
MDA MB 231 Amplifications Deletions
Table 1 (Continued)
High-level alterations detected by array CGHAvailable online http://breast-cancer-research.com/content/8/1/R9
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(1.3 Mb), 20q13.11-q13.32 (14.8 Mb), 20q13.33 (300 kb)
and 20q13.33-tel (1.4 Mb). The gene encoding prefoldin 4
(PFDN4) located within 20q13.11-13.32 has been shown to
be overexpressed in those cell lines in which it is amplified,
including BT-474 [18]. This chromosome arm also harbors
regions of loss at 20q11.22 (650 kb) and 20q11.23-13.11
(7,150 kb) that have not previously been reported.
ZR-75-30 genome
In total, 11 high-level losses and 13 high-level gains were iden-
tified in ZR-75-30. Multiple discrete alterations were observed
on chromosome arms frequently implicated in breast cancer,
including 1p (four deletions), 8q (eight amplicons) and 17q
(seven amplicons and four deletions). Novel segmental losses
of varying sizes were detected at 4q21.1 (150 kb), 11q13.5-
qter (57.6 Mb) and 21q11.2-q22.11 (16.3 Mb). The discrete
high-level amplifications on 8q at 8q11.21 (700 kb), 8q13.3
(500 kb) and 8q22.1 (700 kb) encompassed interesting gene
loci such as those for the following: protein kinase DNA-acti-
vated catalytic subunit (PRKDC), which might have a role in
DNA repair and non-homologous DNA end joining; transient
receptor potential cation channel A1 (ANKTM1), which when
overexpressed, affects normal eukaryotic cell growth; and cad-
herin 17 (CDH17), which shares structural features with the
cadherin superfamily of calcium-dependent cell–cell adhesion
proteins [44-47].
UACC 893 genome
High-level gains at 11q13-q14 have been documented in
UACC 893 [14]. We also observed this alteration (11q13.3-
q14.3, 24.7 Mb); however, an additional discrete high-level
gain at 11q22.1 (600 kb) was also discovered, which inter-
rupts a portion of the gene locus for contactin 5 (CNTN5), a
neural adhesion molecule. A novel gain at 7p21.1 (700 kb)
was also detected that encompasses several gene loci, includ-
ing those for anterior gradient 2 (AGR2) and breast cancer
membrane protein (BCMP1). AGR2 has been shown to be
positively correlated with estrogen receptor expression and
negatively with epidermal growth factor receptor expression in
breast cancer tissue [48]. A loss at 16p12.1 (1,400 kb) was
also observed.
SK-BR-3 genome
Amplifications at 3p22-pter in SK-BR-3 have previously been
reported [13,14]. We observed a 400 kb amplification at
3p22.2 as well as two novel regions of high-level amplification
at 3q25.1 (700 kb) and 3q22.3-q23 (2,000 kb). Figure 3b
shows FISH confirmation of this amplification. Genetic altera-
tions of 8q seem to be complex in SK-BR-3. We observed the
three previously reported regions of gain at 8q13.2-q21.13
(10.6 Mb), 8q21.2-q21.3 (6 Mb) and 8q23.2-q24.21 (17 Mb).
However, we also identified three distinct amplicons within the
6 Mb region (8q21.2 (300 kb), 8q21.3 (550 kb) and 8q21.3
(500 kb)) and also four distinct high-level peaks within the 17
Mb gain described above: 8q23.3 (750 kb), 8q23.3 (350 kb),
8q24.12 (800 kb) and 8q24.21 (700 kb, contains c-MYC).
We also observed four regions of deletion not previously
reported on 8q: 8q21.3-q22.1 (6 Mb), 8q22.3-q23.1 (4.9
Mb), 8q24.22 (1.6 Mb) and 8q24.23-q24.3 (3.8 Mb). In addi-
tion to losses on chromosomes 3 and 8, our analysis has also
identified novel regions of loss at 12q23.3-q24.11 (1.4 Mb)
and 12q24.21-q24.31 (5.4 Mb) and further delineated a
17q12 gain into two distinct high-level gains at 17q11.1-11.2
(3.2 Mb) and 17q12-21.2 (3.4 Mb). In addition a previously
reported gain of 17q24-qter fine mapped to a 1,550 kb ampli-
con at 17q25.3 [13,14].
MDA-MB-231 genome
MDA-MB-231 possessed the fewest number of high-level
alterations. Gains at 6p have previously been reported
[14,49]; however, two distinct regions of high-level gain were
observed within this arm in our analysis: at 6p21.31-21.2 (3.5
6p21.31-21.2 N0479F12 N0450J18 3,510 8q24.13 N0346M14 N0391A17 1,020
6p21.2-21.1 N0259H15 N0769C16 3,290 9p24.2-22.2 N0654D08 N0460F23 14,500
7q35 N0703N05 N0340G20 670 Peak: 9p22.3-22.2 N0141K07 N0460F23 2,000
9p21.3-21.2 N0066P03 N0486D12 5,210
Peak: 9p21.3 N0315I14 N0730N17 280
T47D Amplifications Deletions
3q26.2-29(tel) N0415B12 M2110L16 28,700 12p13.32-12.3 N0312A03 N0056F05 11,700
11q23.3-25(tel) N0081I13 M2013A02 15,200 18p11.32-11.32 N0619C21 N0193E15 349
Deletions 18q21.1 N0699O23 N0093N16 311
8p23.1 N0485I05 M2185F10 1,000 Xq q q q
8p23.1 N0367E11 N0801I21 704
High-level peaks within complex alterations are denoted by italics. Alterations not previously characterized are in bold. Clones beginning with N0 
or F0 belong to the Roswell Park Cancer Institute libraries 11 and 13 (RP11 and RP13), respectively; those beginning with M belong to the 
Caltech-D (CTD) library.
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Mb) and at 6p21.2-21.1 (3.3 Mb). We also observed a novel
670 kb gain at 7q35. Loss at 9p has also been reported; how-
ever, we were able to discern two distinct segmental losses
each containing an amplicon [49-51].
T-47D genome
T-47D was unique in that it possessed three times as many
genomic losses as gains. We observed gains at 18p11.32-
p11.32 (350 kb) and 18q21.1 (300 kb) that have not previ-
ously been reported [14,38,49,51]. Only five genes reside
within the 18q21.1 region: that encoding protein inhibitor of
activated STAT2 (PIAS2), elongin genes TCEB3L2  and
TCEB3L  and hypothetical genes DKFZP564D1378  and
HSPC039.
Common regions of copy number alteration
Gains at 8q, 17q and 20q are among the most frequently doc-
umented alterations in breast cancer. Eight of the nine cell
lines (MDA-MB-231 was the exception) showed high-level
gains at one or more of these chromosome arms. Multiple
alignment of genomic profiles delineated novel minimum
altered regions (MARs) common to these cell lines.
Gains at 8q are arguably the most frequently documented
alteration in a variety of cancers including breast and prostate
cancer [5]. We have highlighted four that were common to
multiple cell lines (Additional file 10). First, a discrete 500 kb
amplicon at 8q13.3 in ZR-75-30 is also included within the
larger alteration at 8q13.33-q21.13 in SK-BR-3. Only one
gene resides within this MAR: that encoding transient recep-
tor potential cation channel subfamily A, member 1 (TRAPA1).
Hyman and coleagues [26] investigated 14 breast cancer cell
lines including BT-474, MCF7, SK-BR-3, T47D and ZR-75-30
with a 13K cDNA array identifying four independent genomic
amplicons at 8q, including 8q21.11-q21.13, 8q21.3, 8q23.3-
q24.14 and 8q24.22. However, the distinct amplicon at
8q13.3 in ZR-75-30 detected by SMRT array CGH was
missed in this study. We observed a second larger MAR at
8q21.2-q21.3 common to alterations in MCF7 and SK-BR-3.
About 20 genes reside in this 5 Mb region, including those
encoding E2F transcription factor, exonuclease GOR and
matrix metalloproteinase 16. A third MAR is located at
8q24.12-q24.21 and is common to MCF-7, ZR-75-30 and
SK-BR-3, whereas lower-level gains are apparent in BT-474,
UACC-893 and MDA-MB-231. Although the genes encoding
zinc finger transcription factor (TRPSI) and eukaryotic
translation initiation factor 3 (EIF3S3) are excluded from this
MAR (c-MYC  is included), some of the cell lines possess
highly complex gains that extend through a much larger region
of the arm and can include the TRPSI and EIF3S3 loci. Sav-
inainen and colleagues [37] reported 41 copies of TRPS1 and
21 copies of EIF3S3 and MYC in Sk-Br-3. The fourth and
most telomeric MAR, 8q24.3, has boundaries defined by a
peak of high-level change within the large complex alteration
8q22.2-q24.3 found in ZR-75-30. MCF-7, BT-474 and
UACC-893 share low-level gains within this region of about
10 genes.
Chromosome 17q gains have been well documented in both
breast cancer cell lines and clinical cases
[14,15,21,39,50,52]. Re-examination of this chromosome arm
at tiling resolution suggests that the 17q amplification is com-
plex and involves multiple but distinct regions (Fig. 4). First we
identified a common high-level gain at 17q25.1 containing a
narrow MAR of 760 kb bounded by BAC clones RP11-76G4
and RP11-552F3. The genes encoding RECQ protein-like 5
(RECQL5), H3 histone family 3B (H3F3B) and growth factor
receptor-bound protein 2 (GRB2) reside within this gene-rich
region, with GRB2 shown to interact with epidermal growth
factor receptor (EGFR) [53]. Second, at 17q23, two separate
amplicons in MCF-7 and one large amplicon in BT-474 have
been described previously, although it is unclear whether
these amplicons are overlapping and harbor the same candi-
date oncogene [25,54]. Our data show the presence of a
large complex alteration in MCF-7 at 17q21.32-q24.3 with a
high-level amplification at 17q23.2. BT-474 contained two
regions of complex alterations at 17q21.32-q23.2 comprising
three distinct high-level peaks as well as a single peak at
17q24.1-q24.3 with a single peak. Similarly, three regions of
high-level gains were observed in ZR-75-30 and one large
region of lower-level gain in UACC-893. Interestingly, our
alignment revealed that the high-level peaks involving the
17q23.2 region in MCF-7, BT-474 and UACC893 do overlap,
defining a 800 kb MAR from RP11-50F16 to RP11-653P10
Figure 2
Magnified submegabase-resolution tiling set (SMRT) array comparative  genomic hybridization profile of the 1p21.1-p11.1 region in MCF-7 Magnified submegabase-resolution tiling set (SMRT) array comparative 
genomic hybridization profile of the 1p21.1-p11.1 region in MCF-7. 
Scale bars labelled ± 1 denote log2 ratio scale. Blue highlighted 
regions indicate the locations of independent amplicons.Available online http://breast-cancer-research.com/content/8/1/R9
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containing candidate genes RPS6KB1,  LOC51136,
FLJ22087, CA4, NY-REN-60, APPBP2 and PPM1D.
Another striking feature identified through our tiling resolution
scan of 17q is the overlapping amplicons at 17q21.32-q21.33
present in BT-474 and ZR-75-30. The 600 kb MAR from
RP11-71G24 to RP11-600O7 harbors the HOXB  family
(HOXB1 to HOXB9). Previously described by Hyman and col-
leagues [26], this amplicon is shown to be present in 10.2%
of primary breast cancers, suggesting the involvement of
developmental genes in breast cancer pathogenesis (Fig. 4).
Chromosome arm 20q has been shown to be frequently ampli-
fied in breast cancer, and amplification of 20q13 is associated
Figure 3
Fluorescence in situ hybridization (FISH) analysis in SK-BR-3 and BT-474 cells Fluorescence in situ hybridization (FISH) analysis in SK-BR-3 and BT-474 cells. (a) SK-BR-3 interphase FISH. Clone RP11-118L18, labeled in 
spectrum green, is located within a 680 kb amplicon at 3q25.1; clone RP11-419H08, labeled in spectrum red, denotes an unchanged site at 
3q11.2. (b) BT-474 interphase FISH. Clone RP11-813P03, labeled in spectrum red, is located at the peak of a 940 kb amplicon at 1q32.1; clone 
RP11-790I13, labeled in spectrum green, is located within an adjacent unchanged region.
Figure 4
17q SMRT aCGH profile of five cell lines sharing multiple minimum altered regions 17q SMRT aCGH profile of five cell lines sharing multiple minimum altered regions. Scale bars labelled ± 1 denote log2 ratio scale. Blue highlighted 
regions indicate the locations of MARs.Breast Cancer Research    Vol 8 No 1    Shadeo and Lam 
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Table 2
Components of the epidermal growth factor receptor pathway affected by copy number change
Gene Locus MCF-7 BT-474 ZR-75-30 UACC-893 Sk-Br-3 MDA-MB-231 T47D
EGF 4q25 +
TGFA 2p13.3 - -
NRG2 5q31.2 +
NRG1 8p12 -- -- -
EGFR 7p12.3-p12.1 + +
ErBB2 17q12 +++ +++ +++ +++
ErBB3 12q13
ErBB4 2q33.3-q34
SH3KBP1 Xp22.12 --
RASA2 3q23 + +
VAV2 9q34.2 + + -
GRB2 17q25.1 ++ +++
PLCG1 20q12 +++ - + +
PLCG2 16q23.2 - - +
RNTRE 10p14 +
SSH3BP1 10p12.1 +
SOS1 2p22.1 - -
PTK2B 8p21.2 - - -- --
SRC 20q11.23 -- +++ ++
NRAS 1p13.2 +++ -
CDC42 1p36.12 -
RAC1 7p22.1 +
RIN1 11q13.2 +
RAF1 3p25.2 + +
MAP3K4 6q26 -- -
MAP3K11 11q13.1 + +++
PAK1 11q13.5 +
ADAM9 8p11.23 +
ADAM12 10q26.2 --- -
ADAM17 2p25.1 +
RAB5a 3p24.3 +
MAP2K1 15q21 -
MAP2K7 19p13.2 -Available online http://breast-cancer-research.com/content/8/1/R9
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with aggressive tumor phenotype, disease recurrence and
reduced duration of survival [20]. We identified multiple copy
number alterations within this cytoband and defined distinct
minimal regions of alteration (Additional file 11). The detection
of a 1.5 Mb MAR at 20q13.2 in MCF-7, BT-474 and SK-BR-3
(RP11-20J8 to RP11-346B3) containing the genes encoding
zinc finger protein 217 (ZNF217), breast cancer-amplified
sequence 1 (BCAS1), cytochrome P450 24A1 (CYP24A1),
prefolding 4 (PFDN4) and docking protein 5 (DOK5) is con-
sistent with previous CGH studies that identified amplification
of this region in breast cancer [18,19]. Similarly, we identified
a MAR at 20q13.31 from RP11-44A6 to RP11-671P16, con-
taining the gene encoding bone morphogenic protein 7
(BMP7),  SPO11  and the gene encoding RNA export 1
(RAE1), corresponding to a previous report in MCF-7 and BT-
474 [43]. A large 1.5 Mb amplification at 20q13.12 has also
been reported in MCF-7 and BT-474 [43]. Our analysis iden-
tified an amplification at 20q13.12-q13.13 common to MCF-
7, BT-474 and SK-BR-3. This spanned BAC clones RP11-
702E3 to RP11-637D22 defining a narrow 680 kb MAR impli-
cating the genes encoding protein kinase C-binding protein
(PRKCBP1) and nuclear receptor coactivator (NCOA3) as
potential oncogenes relevant to breast cancer.
EGFR (ERBB1) and associated pathways
The EGFR and associated pathways have an important role in
several aspects of mammalian cell growth such as cell survival,
proliferation and differentiation [55,56]. The receptor family is
composed of four type-1 tyrosine kinases (ERBB1 to ERBB4)
that dimerize after stimulation by ligand and initiate down-
stream signaling. Receptor ligand recognition is redundant to
some extent, and affinity varies. Although ERBB2 has no
known ligand, it becomes activated after heterodimerization
with other ERBB family members, the most preferred and
MAP2K4 17q11.2 -- --
MAP2K3 17p11.2 - - -
MAP2K6 17q24.3 +++ + +
PDPK1 16p13.3 +
CHN2 7p15.1 + + ++ +
PRKCA 17q24.2 +++ ++ + +
ERK1 16p11.2 +
ERK2 22q11.21 -
MAPK8 10q11.22 +
MAPK9 5q35.3 - -
MAPK14 6p21.31 ++
AKT1 14q32.33 + + +
BAD 11q13.1 +++
LIMK1 7q11.23 + +++ +++ +
PLD1 3q26.31 ++ +
RPS6KA3 Xp22.12 -
FOS 14q24.3 +
JUN 1p32-p31 -
TP53 17p13.1 + -- -
MYC 8q24 +++ ++ +++ + +++ +
ELK1 Xp11.23 - - +
JUN 1p32.1 -
EGF 4q25 +
Scores: +, log2 ratio +0.4 to +0.7; ++, log2 ratio +0.7 to +0.99; +++, log2 ratio more than +1.0; -, log2 ratio -0.4 to -0.7; --, log2 ratio -0.7 to -0.99; 
---, log2 ratio less than -1.0.
Table 2 (Continued)
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potent combination being with ERBB1, whereas the ERBB3
homodimer remains inactive [57].
The redundancy of this pathway suggests its importance as
cells have invested in the mechanisms to make this regulatory
pathway fail safe. We have investigated genomic loci for about
60 genes implicated in this pathway (Table 2) [56]. Overall,
gains were 2.4 times more frequent than losses, and all cell
lines contained at least three loci of change. Our data revealed
that, as expected, the ERBB2 locus is highly amplified in four
cell lines (UACC-893, ZR-75-30, BT-474 and SK-BR-3), and
overexpression has been shown in two of them [9]. Although
amplification of EGFR-interacting genes RECQL5,  H3F3B
and GRB2 has been described above, other frequently altered
loci include c-MYC, LIMK1, PRCKA, CHN2, ERBB2, PYK2,
MAP2K3, MAP2K3 and PLG1. Interestingly, T-47D and the
two  ERBB2-overexpressing lines, BT-474 and SK-BR-3,
share amplifications at five gene loci: MAP2K6,  CHN2,
PRKCA, LIMK1 and c-MYC.
Conclusion
We examined the genomes of seven commonly used breast
cancer cell models in unprecedented detail for segmental
copy number status, cataloging the boundaries of gains and
losses throughout these genomes. In addition, we demon-
strated that copy number alteration of multiple genetic loci
involved in the EGF family of pathways is common in these cell
lines, which suggests that disruption of this frequently dysreg-
ulated pathway in breast cancer may occur at several points in
the signaling cascade and that several disruptions may occur
in combination.
Furthermore, because these cell lines serve as models for
studying the molecular biology of breast cancer, it is essential
to take into account the potential influence of genetic altera-
tions when interpreting biological data. For example, using
these lines to study the EGF family of pathways, multiple
endogenous genetic alterations may have a role in biochemi-
cal and biological observations. Our work provides a compre-
hensive list of high-level segmental gains and losses for each
genome, providing a database of copy number alterations as a
resource for breast cancer research with these cell lines.
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